-
1.发明申请公开(公告)号：US20230002484A1
公开(公告)日：2023-01-05
申请号：US17929824
申请日：2022-09-06
发明人： Karen VEVERKA , Alison WARD
IPC分类号： C07K16/24
摘要： An antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through IL-13Rα1 by binding said receptor and compositions comprising the same for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg, (such as 400 to 600 mg), wherein the disease is modified by a percentage reduction in EASI score in the range −20 to −100% from the baseline.
-
公开(公告)号：US20230091430A1
公开(公告)日：2023-03-23
申请号：US17929874
申请日：2022-09-06
发明人： Karen VEVERKA , Alison WARD
摘要： An antibody, antigen binding fragment thereof and compositions comprising the same, which is an inhibitor of signalling through IL-13Rα1, by binding the said receptor, for use in the treatment of allergic disease, such as atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) in a highly allergic patient where the baseline IgE levels have been established and are at a level of at least 10,000 KU/L+/−2,000.
-
公开(公告)号：US20210277131A1
公开(公告)日：2021-09-09
申请号：US17272243
申请日：2020-03-26
发明人： Alison WARD
摘要： The present disclosure provides a method of treatment comprising inhibiting IL-13R with an antibody or binding fragment thereof specific for the receptor with a VH sequence of SEQ ID NO: 51 or a sequence at least 95% identical thereto, and VL sequence of SEQ ID NO: 53 or a sequence at least 95% identical thereto, wherein said antibody or binding fragment is administered at a dose in the range 600 mg to 900 mg at least once each month, in particular less than twice a month.
-
-
搜索结果
3 条记录 (耗时 0.02 秒)
